Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ855,5857,50,29
KB765766,50,39
PKN58,6158,63-3,70
Msft437,29437,871,59
Nokia3,79053,79450,34
IBM215,75216,50,00
Mercedes-Benz Group AG59,3259,342,99
PFE29,8729,880,40
19.09.2024 11:10:00
Indexy online
AD Index online
select
AD Index online
 

  • 18.09.2024
Macrogenics (NASDAQ Cons)
Závěr k 18.9.2024 Změna (%) Změna (USD) Objem obchodů (ks)
3,30 -1,93 -0,07 613 164
Premarket19.09.2024 10:39:44
Poslední obchod Nákup / Prodej Změna (%) Změna (USD) Objem obchodů (ks)
- 3,26 3,70 - - -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 19.09.2024
Popis společnosti
Obecné informace
Název společnostiMacroGenics Inc
TickerMGNX
Kmenové akcie:Ordinary Shares
RICMGNX.O
ISIN-
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky30.06.2024
Počet zaměstnanců k 31.12.2023 339
Akcie v oběhu k 02.08.2024 62 722 244
MěnaUSD
Kontaktní informace
Ulice9704 Medical Center Drive
MěstoROCKVILLE
PSČ20850
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon13 012 515 172
Fax13012515321

Business Summary: MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.
Financial Summary: BRIEF: For the six months ended 30 June 2024, MacroGenics Inc revenues decreased 47% to $19.9M. Net loss totaled $107.9M vs. income of $19.5M. Revenues reflect Collaborative and other agreements decrease of 85% to $3.5M, Royalty revenue decrease of 39% to $258K, Contract manufacturing decrease of 1% to $5.2M. Net loss reflects Gain on modification of debt decrease from $100.9M (income) to $0K.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSBiological Product (except Diagnostic) Manufacturing
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICCommercial Physical Research
SICBiological Prod's Not Diagnostic



  • Poslední aktualizace: 19.09.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorScott Koenig71
Chief Financial Officer, Senior Vice President, Corporate SecretaryJames Karrels57
Chief Operating OfficerEric Risser5122.02.2022
Senior Vice President - Research, Chief Scientific OfficerEzio Bonvini7014.09.2016
Senior Vice President, Corporate Compliance Officer, General CounselJeffrey Peters53
Senior Vice President - Clinical Development, Chief Medical OfficerStephen Eck6901.07.202001.07.2020
Senior Vice President - Technical OperationsThomas Spitznagel5701.01.2013
Vice President, Controller, TreasurerLynn Cilinski66